More than one in five people who undergo breast cancer surgery or radiation will develop breast cancer-related lymphoedema (BCRL) — a persistent, often uncomfortable swelling that can affect the arm, hand, chest wall, or trunk. For many, manual lymphatic drainage (MLD) becomes a central part of their recovery. But how strong is the evidence behind it?
A 2015 Cochrane systematic review analysed six randomised controlled trials involving 208 participants to find out exactly that. Here is what the data shows — including the cases where MLD adds clear value, and the ones where compression therapy alone may be sufficient.
What Is Breast Cancer-Related Lymphoedema?
BCRL develops when the lymphatic system is damaged during breast cancer treatment. Surgery — particularly axillary lymph node dissection — can reduce the lymphatic network’s capacity to drain fluid from the arm and surrounding tissues. Radiation compounds this by causing scarring and fibrosis within lymph vessels and nodes.
The result is a build-up of protein-rich fluid in the interstitial tissue. Left unmanaged, this fluid accumulates, the tissue loses elasticity, and the risk of skin infections (cellulitis) rises. The swelling is typically classified by excess arm volume: mild (less than 20% excess), moderate (20–40%), and severe (above 40%).
What Is Manual Lymphatic Drainage?
MLD is a specialised hands-on technique designed to stimulate the natural pumping action of the lymph vessels (lymphangions), redirect fluid away from congested areas, and reduce interstitial pressure. It is notably gentle — light, rhythmic strokes rather than conventional deep-tissue massage.
In clinical practice, MLD is rarely given alone. It is most commonly delivered as one of four components within complex decongestive therapy (CDT):
- MLD — to stimulate lymph flow and soften early fibrosis
- Compression therapy — bandaging (Phase 1) or a fitted garment (Phase 2)
- Lymph-reducing exercises — active, repetitive motion performed with compression applied
- Skin care — to reduce infection risk and maintain tissue integrity
CDT operates in two phases: Phase 1 aims to reduce swelling over two to four weeks; Phase 2 focuses on maintaining that reduction through self-management and a compression garment.
What the Evidence Actually Shows
The Cochrane review grouped its six trials into three comparison clusters, and the findings differ meaningfully across them.
MLD Plus Compression Bandaging vs Compression Bandaging Alone
Two trials (83 participants combined) compared intensive compression bandaging with and without the addition of MLD. Compression bandaging alone produced volume reductions of 30% to 38.6%. Adding MLD delivered a statistically significant additional 7.11% reduction (95% CI: 1.75% to 12.47%).
That incremental gain is modest in absolute terms, but it is consistent across two trials with quite different protocols — one starting MLD from the first session, the other adding it only in week three. The consistency of the relative reduction despite different timing is notable and suggests MLD is contributing something distinct from compression alone, not merely augmenting it via extra handling time.
MLD vs Another Active Treatment (Both with Compression)
Three trials compared MLD plus a compression sleeve against a different active treatment plus a compression sleeve — either simple lymphatic drainage (SLD) or intermittent pneumatic compression (IPC). Results here were inconsistent within and across trials, and the three designs were too varied to pool.
One trial favoured MLD over IPC for volume reduction (47 mL difference; P = 0.004). Another showed MLD reducing lymphoedema volume significantly more than self-administered SLD. A third found no significant difference between MLD and therapist-administered SLD. The overall picture when using a standard compression sleeve as the baseline: inconclusive.
MLD Added to Standard Physiotherapy
One trial compared standard physiotherapy (compression garment, exercises, skin care) with and without MLD, and found no between-group difference — both groups achieved roughly 43% reduction from baseline.
Who Benefits Most?
Subgroup analysis — drawing on individual patient data from four of the six trials — produced arguably the review’s most clinically useful finding: MLD appears to benefit those with mild-to-moderate BCRL more than those with moderate-to-severe disease.
When participants were stratified by baseline excess volume, those with less than 23% excess showed a statistically significant additional response to MLD over compression bandaging alone (MD 12.09%; P = 0.05). Above that threshold, the advantage largely disappeared.
The proposed mechanism is intuitive: in milder cases, the lymphatic architecture remains more intact, allowing MLD to genuinely stimulate lymphangion activity and reroute fluid via collateral vessels. In more advanced or fibrotic cases, the lymphatic network may be too compromised to respond to manual stimulation, and compression — which works by altering microvascular pressure — becomes the dominant therapeutic driver.
This does not mean MLD has no role in moderate-to-severe BCRL. It means the evidence currently supports a stronger, more confident role in earlier-stage disease.
Symptoms, Function, and Quality of Life
Across the four trials that measured subjective symptoms (pain, heaviness, tension), both treatment and control groups showed significant improvement from baseline — with no consistent between-group differences. Between 60% and 80% of participants reported feeling better regardless of which treatment they received.
Range of motion results were contradictory: one trial showed improvements in both groups; another showed none. Strength was assessed in a single trial, with no improvements observed in either group. Quality of life data were either unreported or presented only as within-group results, making any firm conclusion impossible.
What this tells us practically: symptom relief is a real and achievable outcome of lymphoedema treatment, but MLD does not appear to be the singular driver. The broader treatment package — compression, exercises, skin care, and clinical contact — likely contributes meaningfully to how patients feel.
Safety Profile
MLD was well tolerated across all six trials. No adverse events were attributed to MLD in any study. The only adverse events reported were related to compression bandaging — one case of a skin reaction, one of elbow discomfort — leading to two withdrawals across the entire body of evidence.
Adherence with MLD sessions was high across the trials that reported it, with almost all participants completing their prescribed sessions.
The Long-term Picture: What Keeps the Swelling Down
Only one trial (Andersen 2000) followed participants beyond the immediate post-treatment period, tracking them for 12 months. By the end of that period, both groups — with and without MLD — had achieved a 66% combined reduction from baseline.
The study’s own conclusion is telling: the long-term outcome was significantly related to continued use of the compression sleeve, not to whether MLD had been given. Once volume had been adequately reduced, participants who maintained compliance with a custom-fitted garment were the ones who kept their gains.
This aligns with the CDT model: Phase 1 reduces the swelling; Phase 2 — which is largely self-managed — preserves it. MLD’s contribution is front-loaded. Its value in the maintenance phase is less clear, and the evidence does not currently support it as a routine Phase 2 intervention.
A Note on Study Quality
The six trials included in this review were small (24–45 participants each) and varied in design. Four of the six did not blind their outcomes assessors, which introduces the risk that measurement may have been influenced by knowledge of group assignment. Individual patient data were available for four trials, which allowed the authors to calculate missing volumetric outcomes and conduct meaningful subgroup analyses — a methodological strength.
The overall evidence base is sufficient to guide clinical practice, but larger, better-powered trials — particularly with longer follow-up and lymphoedema-specific quality of life measures — would add considerably to what we currently know.
Comparison: MLD Add-On vs Compression Bandaging Alone
| Outcome | Compression Bandaging Only | MLD + Compression Bandaging |
|---|---|---|
| Per cent volume reduction | 30–38.6% | Additional 7.11% (P = 0.009) |
| Volume reduction (mL) | Baseline | Borderline significant (+26 mL; P = 0.06) |
| Lymphoedema volume (mL remaining) | — | No significant difference |
| Benefit in mild–moderate BCRL | Moderate | Significant (P = 0.02–0.05) |
| Benefit in moderate–severe BCRL | Primary driver | No significant added benefit |
| Adverse events from treatment | Skin/elbow irritation (rare) | None reported |
| Tolerability | Good | Excellent |
FAQ
What is manual lymphatic drainage used for after breast cancer treatment?
MLD is used to reduce arm swelling caused by breast cancer-related lymphoedema. It is typically delivered as part of complex decongestive therapy, alongside compression bandaging or garments, lymph-reducing exercises, and skin care.
Does MLD work better than compression therapy alone?
When added to intensive compression bandaging, MLD produces a statistically significant additional volume reduction of around 7% compared to compression bandaging on its own. Compression bandaging remains the primary driver of swelling reduction; MLD contributes an incremental benefit on top of it.
Who benefits most from MLD for lymphoedema?
The current evidence points to people with mild-to-moderate BCRL — generally those with less than 23% excess arm volume at baseline — as the most likely responders. In this group, the lymphatic system is relatively intact and better able to respond to manual stimulation. Those with more advanced or fibrotic lymphoedema tend not to show a significant additional benefit from MLD over compression alone.
Is manual lymphatic drainage safe for breast cancer survivors?
Yes. Across all six trials included in the Cochrane review, MLD was well tolerated with no adverse events attributed to the technique itself. Adherence rates were high, and the intervention was consistently described as safe in this population.
How many MLD sessions are typically needed in Phase 1 treatment?
Trials in the Cochrane review used between five and twenty sessions in Phase 1, delivered daily or five days per week across two to four weeks. The standard intensive phase of CDT typically runs for two to four weeks, after which the focus shifts to self-management and garment use.
Does MLD need to continue long-term?
The evidence does not support MLD as a routine long-term maintenance intervention. One-year follow-up data suggest the key factor in sustaining volume reduction after Phase 1 is consistent use of a custom-fitted compression sleeve — not continued MLD. That said, individual clinical needs vary and some people may benefit from periodic treatment.
Can occupational therapists deliver MLD for lymphoedema?
Occupational therapists with specialist training in lymphoedema management can assess and treat BCRL, including delivering MLD within a CDT programme. At Lifeweavers, lymphoedema management is part of our cancer rehabilitation programme“, which supports people through post-surgical recovery and long-term maintenance.
Plan the best version of yourself with us
We are here to do it with you. As a progressive rehab therapy team, there are no case too big or small for us. What matters is to achieve quality – of life and outcomes. You can reach our team via WhatsApp for a no-obligation conversation about your situation, your goals, and how we can help.